These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19437494)

  • 1. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development.
    Delang L; Paeshuyse J; Vliegen I; Leyssen P; Obeid S; Durantel D; Zoulim F; Op de Beeck A; Neyts J
    Hepatology; 2009 Jul; 50(1):6-16. PubMed ID: 19437494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
    Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
    Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
    Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
    Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are statins a viable option for the treatment of infections with the hepatitis C virus?
    Verpaalen B; Neyts J; Delang L
    Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon.
    Ikeda M; Kato N
    J Pharmacol Sci; 2007 Oct; 105(2):145-50. PubMed ID: 17928739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.
    Malcolm BA; Liu R; Lahser F; Agrawal S; Belanger B; Butkiewicz N; Chase R; Gheyas F; Hart A; Hesk D; Ingravallo P; Jiang C; Kong R; Lu J; Pichardo J; Prongay A; Skelton A; Tong X; Venkatraman S; Xia E; Girijavallabhan V; Njoroge FG
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1013-20. PubMed ID: 16495264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.
    Delang L; Scheers E; Grabner M; Verpaalen B; Helsen N; Vanstreels E; Daelemans D; Verfaillie C; Neyts J
    Biochem Pharmacol; 2015 Aug; 96(3):190-201. PubMed ID: 26070251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
    Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
    Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
    Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
    J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
    Vliegen I; Paeshuyse J; Zhong W; Neyts J
    Antiviral Res; 2015 Aug; 120():112-21. PubMed ID: 26036224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
    Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
    Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.